We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+6.24%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.13B
AUM Growth
-$114M
Cap. Flow
-$40.3M
Cap. Flow %
-1.89%
Top 10 Hldgs %
71.72%
Holding
45
New
2
Increased
3
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SURF
Surface Oncology, Inc. Common Stock
SURF
+$48M
2
LITS
Lite Strategy Inc
LITS
+$17.5M
3
CBIO
Crescent Biopharma
CBIO
+$8.68M
4
ARDX icon
Ardelyx
ARDX
+$5.81M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$3.37M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$79.4M
2
IMMU
Immunomedics Inc
IMMU
+$40.5M
3
AQ
Aquantia Corp. Common Stock
AQ
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
2 Technology 0.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$463M 21.71%
10,420,555
– –
ADAP
2
DELISTED
Adaptimmune Therapeutics
ADAP
$158M 7.41%
13,332,611
– –
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.3B
$154M 7.19%
4,912,306
– –
CBIO
4
Crescent Biopharma
CBIO
$546M
$147M 6.87%
90,890
+5,049
+6% +$8.68M
MRSN
5
DELISTED
Mersana Therapeutics
MRSN
$145M 6.81%
325,771
– –
SENS icon
6
Senseonics Holdings Inc
SENS
$255M
$127M 5.95%
1,544,413
– –
CRSP icon
7
CRISPR Therapeutics
CRSP
$4.69B
$123M 5.76%
2,090,678
-1,393,786
-40% -$79.4M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$87.5M 4.1%
6,460,851
– –
OBSV
9
DELISTED
ObsEva SA Ordinary Shares
OBSV
$69.4M 3.25%
4,586,563
– –
ARDX icon
10
Ardelyx
ARDX
$1.24B
$56.7M 2.66%
15,335,047
+1,251,465
+9% +$5.81M
RARX
11
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$54.7M 2.56%
5,493,636
– –
SURF
12
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$54.1M 2.53%
+3,315,149
New +$48M
AKAO
13
DELISTED
Achaogen Inc
AKAO
$45.2M 2.12%
5,215,128
– –
SYBX
14
DELISTED
Synlogic
SYBX
$41.6M 1.95%
281,961
– –
AVEO
15
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$40.1M 1.88%
1,778,372
+142,103
+9% +$3.37M
DERM
16
DELISTED
Dermira, Inc.
DERM
$32.3M 1.51%
3,506,649
– –
LXRX icon
17
Lexicon Pharmaceuticals
LXRX
$1.03B
$28.6M 1.34%
2,382,286
– –
CMTA
18
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$28.2M 1.32%
2,141,697
– –
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.95B
$27.1M 1.27%
4,808,483
– –
SBBP
20
DELISTED
Strongbridge Biopharma plc.
SBBP
$24.8M 1.16%
4,141,308
– –
LITS
21
Lite Strategy Inc
LITS
$32.1M
$22.5M 1.06%
+286,029
New +$17.5M
GNCA
22
DELISTED
Genocea Biosciences, Inc.
GNCA
$21.3M 1%
3,125,000
– –
CTIC
23
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$18.7M 0.87%
3,750,000
– –
VRNA
24
DELISTED
Verona Pharma
VRNA
$16.7M 0.78%
1,219,674
– –
KA
25
DELISTED
Kineta, Inc. Common Stock
KA
$15.5M 0.73%
39,691
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q2 2018 Portfolio in Review

As of Q2 2018, NEA Management Company held 45 positions worth $2.13B, down 5.1% from $2.25B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

NEA Management Company's Q2 2018 filing shows 2 new, 3 increased, 1 reduced and 2 closed positions. Its largest new stake was Surface Oncology, Inc. Common Stock: 3,315,149 shares worth $54.1M. The largest sale was CRISPR Therapeutics, an estimated $79.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier, followed by Technology.

  • NEA Management Company's largest Q2 2018 buy was Surface Oncology, Inc. Common Stock: 3,315,149 shares worth $54.1M.
  • NEA Management Company added most to Crescent Biopharma in Q2 2018, an estimated $8.68M increase.
  • NEA Management Company's biggest Q2 2018 reduction was CRISPR Therapeutics, cutting an estimated $79.4M.
  • NEA Management Company fully exited Immunomedics Inc in Q2 2018, selling an estimated $40.5M.
  • NEA Management Company's ten largest holdings make up 72% of its $2.13B portfolio in Q2 2018.
  • NEA Management Company opened 2 new positions and closed 2 in Q2 2018.
  • NEA Management Company's portfolio value fell 5.1% quarter-over-quarter to $2.13B.

Based on NEA Management Company's 13F filing for Q2 2018, filed 9 Aug 2018.